Novavax Stock Tumbled 19% in Morning Trading

Tiger Newspress2022-05-10

Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.

Revenue rose to $704 million, from $447 million a year ago.

Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.

Novavax said it has been "successful" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.

"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate," Chief Executive Stanley C. Erck said in a statement.

Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.

The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（8）

Miketee74
·2022-05-11
Speechless! Gain also drop!! Just because not meet expectations. The question is "are those expectation valid?".
Reply
Like
Report
Hhee
·2022-05-11
Ok
Reply
Like
Report
Pepeflabs
·2022-05-11
Ok
Reply
6
Report
Pepeflabs
·2022-05-11
Bonk
Reply
5
Report
Huatkor
·2022-05-10
😡
Reply
Like
Report
GangKK
·2022-05-10
[Call] [Call] [Call] [Call] [Call] [Call] [Call] [Call]
Reply
2
Report
Kevin92
·2022-05-10
Like
Reply
2
Report
Damien Khoo
·2022-05-10
Huge paper loss
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1194024573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-10 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194024573","market":"us","top_or_hot":-1,"title":"Novavax Stock Tumbled 19% in Morning Trading","media":"Tiger Newspress","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n2022-05-10 21:40 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1194024573","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","pubTimestamp":1652190050,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"Novavax股票在早盘交易中暴跌19%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9065453971,"gmtCreate":1652229493893,"gmtModify":1676535056767,"author":{"id":"3585785590601618","authorId":"3585785590601618","name":"Miketee74","avatar":"https://community-static.tradeup.com/news/09ea58a03e562828bff08f7347bbcdb4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585785590601618","authorIdStr":"3585785590601618"},"htmlText":"Speechless! Gain also drop!! Just because not meet expectations. The question is \"are those expectation valid?\".&nbsp;","listText":"Speechless! Gain also drop!! Just because not meet expectations. The question is \"are those expectation valid?\".&nbsp;","text":"Speechless! Gain also drop!! Just because not meet expectations. The question is \"are those expectation valid?\".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065453971","repostId":1194024573,"repostType":4,"repost":{"id":"1194024573","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652190050,"share":"https://ttm.financial/m/news/1194024573?lang=&edition=fundamental","pubTime":"2022-05-10 21:40","market":"us","language":"en","title":"Novavax Stock Tumbled 19% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","media":"Tiger Newspress","summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-10 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194024573","content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9065249803,"gmtCreate":1652213988402,"gmtModify":1676535051595,"author":{"id":"3573194938156893","authorId":"3573194938156893","name":"Hhee","avatar":"https://static.tigerbbs.com/03925b51c18198975d8ae9335c78a30d","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"3573194938156893","authorIdStr":"3573194938156893"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065249803","repostId":1194024573,"repostType":4,"repost":{"id":"1194024573","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652190050,"share":"https://ttm.financial/m/news/1194024573?lang=&edition=fundamental","pubTime":"2022-05-10 21:40","market":"us","language":"en","title":"Novavax Stock Tumbled 19% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","media":"Tiger Newspress","summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-10 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194024573","content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9065255827,"gmtCreate":1652207127769,"gmtModify":1676535051477,"author":{"id":"3573162818118967","authorId":"3573162818118967","name":"Pepeflabs","avatar":"https://static.tigerbbs.com/bb2ce4a85b6af8ab6f45834a991797c6","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":2,"crmLevelSwitch":1,"idStr":"3573162818118967","authorIdStr":"3573162818118967"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065255827","repostId":1194024573,"repostType":4,"repost":{"id":"1194024573","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652190050,"share":"https://ttm.financial/m/news/1194024573?lang=&edition=fundamental","pubTime":"2022-05-10 21:40","market":"us","language":"en","title":"Novavax Stock Tumbled 19% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","media":"Tiger Newspress","summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-10 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194024573","content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9065255111,"gmtCreate":1652207113633,"gmtModify":1676535051476,"author":{"id":"3573162818118967","authorId":"3573162818118967","name":"Pepeflabs","avatar":"https://static.tigerbbs.com/bb2ce4a85b6af8ab6f45834a991797c6","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":2,"crmLevelSwitch":1,"idStr":"3573162818118967","authorIdStr":"3573162818118967"},"htmlText":"Bonk","listText":"Bonk","text":"Bonk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065255111","repostId":1194024573,"repostType":4,"repost":{"id":"1194024573","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652190050,"share":"https://ttm.financial/m/news/1194024573?lang=&edition=fundamental","pubTime":"2022-05-10 21:40","market":"us","language":"en","title":"Novavax Stock Tumbled 19% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","media":"Tiger Newspress","summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-10 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194024573","content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9065231904,"gmtCreate":1652194751508,"gmtModify":1676535049980,"author":{"id":"3581919183376534","authorId":"3581919183376534","name":"Huatkor","avatar":"https://static.tigerbbs.com/6f3897aace055b5fa9f58089c1e880d8","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581919183376534","authorIdStr":"3581919183376534"},"htmlText":"😡","listText":"😡","text":"😡","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065231904","repostId":1194024573,"repostType":4,"repost":{"id":"1194024573","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652190050,"share":"https://ttm.financial/m/news/1194024573?lang=&edition=fundamental","pubTime":"2022-05-10 21:40","market":"us","language":"en","title":"Novavax Stock Tumbled 19% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","media":"Tiger Newspress","summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-10 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194024573","content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9065671160,"gmtCreate":1652192395750,"gmtModify":1676535049187,"author":{"id":"4090807166052950","authorId":"4090807166052950","name":"GangKK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4090807166052950","authorIdStr":"4090807166052950"},"htmlText":"[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;","listText":"[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;","text":"[Call] [Call] [Call] [Call] [Call] [Call] [Call] [Call]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065671160","repostId":1194024573,"repostType":2,"repost":{"id":"1194024573","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652190050,"share":"https://ttm.financial/m/news/1194024573?lang=&edition=fundamental","pubTime":"2022-05-10 21:40","market":"us","language":"en","title":"Novavax Stock Tumbled 19% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","media":"Tiger Newspress","summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-10 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194024573","content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9065654178,"gmtCreate":1652191167594,"gmtModify":1676535048777,"author":{"id":"3576274545052910","authorId":"3576274545052910","name":"Kevin92","avatar":"https://static.tigerbbs.com/c5ff4addbbdb8d9d15fec29f9709b0c3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576274545052910","authorIdStr":"3576274545052910"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065654178","repostId":1194024573,"repostType":4,"repost":{"id":"1194024573","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652190050,"share":"https://ttm.financial/m/news/1194024573?lang=&edition=fundamental","pubTime":"2022-05-10 21:40","market":"us","language":"en","title":"Novavax Stock Tumbled 19% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","media":"Tiger Newspress","summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-10 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194024573","content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9065659543,"gmtCreate":1652190597882,"gmtModify":1676535048653,"author":{"id":"3576444918223783","authorId":"3576444918223783","name":"Damien Khoo","avatar":"https://community-static.tradeup.com/news/f08d9f6bdc3c0038e9aa81591b4df363","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":4,"crmLevelSwitch":0,"idStr":"3576444918223783","authorIdStr":"3576444918223783"},"htmlText":"Huge paper loss","listText":"Huge paper loss","text":"Huge paper loss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065659543","repostId":1194024573,"repostType":2,"repost":{"id":"1194024573","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652190050,"share":"https://ttm.financial/m/news/1194024573?lang=&edition=fundamental","pubTime":"2022-05-10 21:40","market":"us","language":"en","title":"Novavax Stock Tumbled 19% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194024573","media":"Tiger Newspress","summary":"The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.","content":"<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Tumbled 19% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Tumbled 19% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-10 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.<img src=\"https://static.tigerbbs.com/84d28a2a5dda303c3294b22e4133488f\" tg-width=\"878\" tg-height=\"665\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194024573","content_text":"Novavax Stock Tumbled 19% in Morning Trading. The biotech company reported its first profitable quarter, but not by as much as Wall Street expected.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted an emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":62,"commentSize":8,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}